HomeCompaniesIMPACT Therapeutics
Company
IMPACT Therapeutics
HKEX: 7630
Shanghai, China-based, HKEX-listed biotech developing synthetic-lethality-based precision cancer therapies. Its PARP inhibitor senaparib is already approved and reimbursed in China; Pharmanovia holds the EU licensing rights this CHMP opinion advances.
1 story
Regulatory News has published 1 story about IMPACT Therapeutics on 30 September 2026, sourced to the primary record — the regulator’s decision, the company’s filing or its own announcement. This page is generated from that coverage. Last updated 30 September 2026.
This page is generated from Regulatory News’ editorial coverage of IMPACT Therapeutics. It is not an advertisement.
On the record
- Company
- IMPACT Therapeutics, Inc. (HKEX: 7630)
- Headquarters
- Shanghai (Pudong), China
- Founded
- 2009
- Regulator
- European Medicines Agency (CHMP)
Each line is taken from the most recent story of ours that states it.
Products in our coverage
Our coverage
